Provided by Tiger Trade Technology Pte. Ltd.

Royalty Pharma plc

61.31
+0.73001.21%
Pre-market: 61.990.6800+1.11%05:11 EDT
Volume:2.33M
Turnover:142.36M
Market Cap:35.37B
PE:32.89
High:61.60
Open:60.53
Low:60.37
Close:60.58
52wk High:62.13
52wk Low:34.08
Shares:576.94M
Float Shares:392.53M
Volume Ratio:0.94
T/O Rate:0.59%
Dividend:0.91
Dividend Rate:1.48%
EPS(TTM):1.86
EPS(LYR):1.78
ROE:13.97%
ROA:5.09%
PB:5.18
PE(LYR):34.42

Loading ...

Royalty Pharma Q1 Operating Income USD 563 Million

THOMSON REUTERS
·
May 06

Royalty Pharma Q1 Net Income USD 468 Million

THOMSON REUTERS
·
May 06

Royalty Pharma CFO Terrance Coyne disposes of 34,791 shares worth $1.73 million

Reuters
·
May 01

Earning Preview: Royalty Pharma plc Q1 revenue is expected to increase by 64.58%, and institutional views are constructive

Earnings Agent
·
Apr 29

Royalty Pharma Is Maintained at Buy by UBS

Dow Jones
·
Apr 22

UBS Adjusts Royalty Pharma Price Target to $57 From $51, Maintains Buy Rating

MT Newswires Live
·
Apr 21

Royalty Pharma Keeps Quarterly Dividend at $0.235 per Share, Payable June 10 to Shareholders of Record as of May 15

MT Newswires Live
·
Apr 17

Press Release: Royalty Pharma Declares Second Quarter 2026 Dividend

Dow Jones
·
Apr 17

Royalty Pharma forecasts 2026 portfolio receipts of $3.28 billion-$3.43 billion

Reuters
·
Apr 16

Royalty Pharma to report first-quarter results, host conference call and webcast

Reuters
·
Apr 16

Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026

THOMSON REUTERS
·
Apr 16

Royalty Pharma announces annual shareholder meeting

Reuters
·
Apr 11

Royalty Pharma Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Apr 11

Royalty Pharma price target raised to $63 from $61 at Morgan Stanley

TIPRANKS
·
Apr 10

Royalty Pharma CFO Terrance Coyne reports $1.7 million Class A share sale

Reuters
·
Apr 03

Zymeworks Appoints Kristin Stafford CFO

MT Newswires Live
·
Apr 01

Zymeworks appoints Kristin Stafford as CFO effective April 1, 2026

Reuters
·
Apr 01

Royalty Pharma reports co-funding agreement with Johnson & Johnson for JNJ-4804

TIPRANKS
·
Mar 30

Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases

THOMSON REUTERS
·
Mar 30

Royalty Pharma - Announces $500 Mln R&D Co-Funding Agreement With Johnson & Johnson for 2026-2027

THOMSON REUTERS
·
Mar 30